UNMC scientists invent new compounds to treat cancerResearchers at the University of Nebraska Medical Center created a molecule capable of specifically inhibiting the NF-κB pathway, a key target involved in a variety of cancers and other diseases.
The NF-κB pathway is often overactive in a number of cancers. Therefore, new ways to shut off this pathway could yield important new cancer treatments.
Amarnath Natarajan, Ph.D., and his team developed a small molecule called 36-252 that destroys key members of the NF-κB pathway—specifically the proteins IKKβ and IKKα. In ovarian cancer cell studies, 36-252 effectively inhibited cell growth at nanomolar concentrations, stimulated cell death (apoptosis), and effectively inhibited NF-κB activity. 36-252 was also effective at destroying ovarian cancer stem-like cells.
UNeMed is interested in forming collaborations with industry to further explore the potential of 36-252 as a novel therapy of the treatment of cancer and other diseases associated with overactive NF-κB.
To discuss licensing opportunities please contact Matt Boehm, Ph.D., at email@example.com or 402-536-9881.